Skip to main content
Premium Trial:

Request an Annual Quote

Hexagon Bio Raises $61M in Private Financing Round

NEW YORK — Drug discovery company Hexagon Bio said on Wednesday that it has raised $61 million in private financing.

The funding round was led by Nextech Invest with participation from new investors SoftBank Vision Fund 2* and Casdin Capital and existing investors The Column Group, 8VC, and Two Sigma Ventures.

Hexagon has developed a platform that combines machine learning, genomics, synthetic biology, and automation to identify therapeutic small molecules and their protein targets directly from microbial genomes. With the new funding, the firm aims to expand its microbial genomics database and accelerate its drug discovery efforts, with an initial focus on infectious disease and cancer.

"Microbial genomes are an incredibly rich source of diverse, potent, and drug-like compounds that, as a result of millions of years of evolution, provide elegant solutions to human therapeutic targets that have eluded traditional screening approaches," Hexagon cofounder and CEO Maureen Hillenmeyer said in a statement.

About a year ago, Menlo Park, California-based Hexagon raised $47 million in a Series A round.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.